R&D Strategy & Pipeline

R&D Strategy & Pipeline

R&D Strategy & Pipeline

Committed to innovation, Da Volterra develops products intended to protect the intestinal microbiota or harness its potential to help prevent and cure human diseases.

Products DiscoveryPreclinicalPhase 1Phase 2Phase 3Market
DAV132Protecting the intestinal microbiota during antibiotic treatments      
DAV121Preventing Antibiotic Resistance with Carbapenems  
Microbiome Discovery PlatformDiscovering metagenomic and metabolomic targets in the intestinal microbiota to support the development of novel therapeutic strategies 

Over the years since inception, we have gathered a unique in-house expertise on the intestinal microbiota and its links to the different body functions, antibacterial drugs and other drugs disrupting the microbiota as well as drug delivery technologies.